CGbio Co., Ltd. (CEO Hyunseung Yoo) signed an MOU for joint research on SVF (Stromal Vascular Fraction) with BIO Plastic Surgery Clinic (CEO Inchang Jo), and SVF in the field of tissue regeneration It was announced on the 12th that it would start a study to prove the therapeutic effect of transplantation.
The signing ceremony was held on the 4th in the seminar room of BIO Plastic Surgery Clinic with the participation of officials from both companies, including CEO Yoo Hyun-seung of CG Bio and CEO Jo In-chang of BIO Plastic Surgery Clinic.
According to the MOU, CG Bio will collaborate with BIO Plastic Surgery for research and data collection to prove the therapeutic effect of SVF transplantation in indications such as wound and scar regeneration, breast enlargement, and anti-aging skin booster. To establish CG Bio’s SVF research branch in BIO Plastic Surgery Clinic. CG Bio’s SVF automatic extraction device Cell Unit (CELLUNIT) will be used for these research activities and data collection.
SVF refers to the remaining cell population in adipose tissue except for adipocytes, and in addition to adipose-derived stem cells, various cells including vascular endothelial cells, fibroblasts, immune cells, and muscle cells exist. Therefore, in addition to cell differentiation, which is the main function of stem cells, △vascularization and blood supply △wound recovery and tissue reconstruction △apoptosis and delay prevention △immune factor regulation △environmental cell activation are also performed.
Also, unlike adipose-derived stem cells that are extracted through culture, SVF is known to have a relatively low risk of cancer because it does not undergo a culture process.
CGbio CEO Yoo Hyun-seung said, “We plan to expand the treatment area where SVF transplantation can be helpful by continuously revealing the clinical efficacy and safety of SVF extracted through cell units.”